AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma

The FDA has assigned the application standard review and a Prescription Drug User Fee Act target action date of March 31, 2021.